Sound Pharmaceuticals is pleased to announce that the FDA has allowed its pivotal Phase 3 clinical protocol for SPI-1005 in the Treatment of Patients with Meniere’s Disease (STOPMD-3). Read More
University of Oxford and Sound Pharmaceuticals complete Phase 2 Bipolar Disorder Study with SPI-1005
The University of Oxford and Sound Pharmaceuticals (SPI), are pleased to announce the successful completion of a Phase 2a study testing SPI-1005 as a new treatment for bipolar disorder (BPD). Read More
